

# Kazuko Nagase

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5882324/publications.pdf>

Version: 2024-02-01

8  
papers

147  
citations

1307594  
7  
h-index

1588992  
8  
g-index

8  
all docs

8  
docs citations

8  
times ranked

167  
citing authors

#	ARTICLE	IF	CITATIONS
1	Xilei San Ameliorates Experimental Colitis in Rats by Selectively Degrading Proinflammatory Mediators and Promoting Mucosal Repair. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-10.	1.2	15
2	Crohn's disease complicated by hepatitis B virus successfully treated with the use of adsorptive depletion of myeloid lineage leucocytes to suppress inflammatory cytokine profile. Cytotherapy, 2014, 16, 821-825.	0.7	8
3	Questionnaire Based Assessment of Patients' Acceptability of Leukocytapheresis for the Treatment of Inflammatory Bowel Disease. Therapeutic Apheresis and Dialysis, 2013, 17, 490-497.	0.9	3
4	Placebo controlled evaluation of Xilei San, a herbal preparation in patients with intractable ulcerative proctitis. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1808-1815.	2.8	38
5	Immunoregulatory Effects of Adsorptive Granulocyte and Monocyte Apheresis in Patients with Drug Refractory Crohn's Disease. Therapeutic Apheresis and Dialysis, 2011, 15, 367-373.	0.9	12
6	A Suppository Chinese Medicine (Xilei-san) for Refractory Ulcerative Proctitis: A Pilot Clinical Trial. Digestion, 2007, 75, 146-147.	2.3	16
7	Detection of Specific IgE Antibodies to Nafamostat Mesilate as an Indication of Possible Adverse Effects of Leukocytapheresis using Nafamostat Mesilate as Anticoagulant. Therapeutic Apheresis and Dialysis, 2004, 8, 45-51.	0.9	17
8	Complications of Leukocytapheresis. Therapeutic Apheresis and Dialysis, 1998, 2, 120-124.	0.6	38